Table 1. Baseline patient characteristics.
No (%) | |
---|---|
Sex | |
Male | 9 (50%) |
Female | 9 (50%) |
Age, median | 54 (range, 29–73) |
Primary tumor site | |
Head | 10 (55%) |
Body or tail | 7 (39%) |
Multicentric | 1 (6%) |
Baseline CA19-9 | |
Normal | 4 (22%) |
>1 & ≤ 2 x UNL | 4 (22%) |
>2 x UNL | 10 (56%) |
Regional lymph node metastasis | 10 (56%) |
No. of chemotherapy cycles | 6 (range, 3–13) |
Surgery | 12 (67%) |
R0 | 9 (75%) |
R1 | 3 (25%) |
Postoperative treatment (n = 12) | |
No | 2 (17%) |
Chemotherapy only | 7 (58%) |
CCRT only | 2 (17%) |
CCRT followed by chemotherapy | 1 (8%) |
Postop chemotherapy regimen | |
Gemcitabine | 3 (38%) |
FOLFIRINOX | 5 (62%) |
UNL: upper normal limit; CCRT: concurrent chemoradiotherapy.